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Abstract
Background: Today, while there are effective drugs that reduce the risk of osteoporotic fracture, yet there are no
broadly accepted criteria that can be used to estimate risks and decide who should receive treatment. One of the
actual priorities of clinical research is to develop a set of simple and readily-available clinical data that can be used
in routine clinical practice to identify patients at high risk of bone fracture, and to establish thresholds for
therapeutic interventions. Such a tool would have high impact on healthcare policies. The main objective of the
ESOSVAL-R is to develop a risk prediction scale of osteoporotic fracture in adult population using data from the
Region of Valencia, Spain.
Methods/Design: Study design: An observational, longitudinal, prospective cohort study, undertaken in the Region
of Valencia, with an initial follow-up period of five years; Subjects: 14,500 men and women over the age of 50,
residing in the Region and receiving healthcare from centers where the ABUCASIS electronic clinical records
system is implanted; Sources of data: The ABUCASIS electronic clinical record system, complemented with hospital
morbidity registers, hospital Accidents & Emergency records and the Regional Ministry of Health’s mortality register;
Measurement of results: Incident osteoporotic fracture (in the hip and/or major osteoporotic fracture) during the
study’s follow-up period. Independent variables include clinical data and complementary examinations; Analysis: 1)
Descriptive analysis of the cohorts’ baseline data; 2) Upon completion of the follow-up period, analysis of the
strength of association between the risk factors and the incidence of osteoporotic fracture using Cox’s proportional
hazards model; 3) Development and validation of a model to predict risk of osteoporotic fracture; the validated
model will serve to develop a simplified scale that can be used during routine clinical visits.
Discussion: The ESOSVAL-R study will establish a prediction scale for osteoporotic fracture in Spanish adult
population. This scale not only will constitute a useful prognostic tool, but also it will allow identifying intervention
thresholds to support treatment decision-making in the Valencia setting, based mainly on the information
registered in the electronic clinical records.
Background
Osteoporosis is a systemic disease of the skeleton, char-
acterized by the deterioration of the bones’ macro and
microstructures that leads to a loss in bone mass and
the reduction in the bones’ resistance increasing
propensity to bone fracture [1]. At present, osteoporosis
is highly prevalent, with an incidence that is rising due
to the greater life expectancy of today’s societies. Osteo-
porosis is a silent disease, yet has a major clinical impact
because of its association with an increased risk of frac-
ture. The most relevant events associated with osteo-
porosis are osteoporotic fractures and their
consequences. Most frequently, events occur in the dor-
solumbar spine, the hip and the wrist.
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Hip fracture is the most serious consequence of osteo-
porosis. In Spain it is estimated an incidence of hip frac-
ture in people over 50 years-old between 2-3 cases per
1,000 inhabitants/year [2-5], with a male/female distri-
bution of 2-3:5. These figures increase considerably with
age, and in subjects over the age of 60, the incidence of
hip fracture is 5-7 cases per 1,000 inhabitants/year, with
greater occurrence among women [6,7]. Regarding ver-
tebral fractures, prevalence and incidence rates vary
considerably, depending on the population and the cri-
teria used to define a fracture. In subjects over the age
of 50 in the Region of Asturias, Spain, prevalence
was 27.2% in women and 20.8% in men [8]. In a popula-
tion-based study recently conducted by our group in
post-menopausal women in the city of Valencia, the pre-
valence of morphometric vertebral fracture was 21% in
women over 50, and 46% in women over 75 [9].
According to data recently published in the Region of
Valencia, Spain [10] the annual number of hospital
admissions for fractures of the hip, vertebrae and fore-
arm (fractures that are not due to major traumatism
assessed using the Hospital Discharge Data Set) has
increased in absolute values in the population over the
age of 64. Discharges in the Region for hip fracture have
gone from 3,329 in 2000 to 4,510 in 2006. Distal frac-
tures of the forearm went from 341 to 496 during the
same period. The number of vertebral fractures -that
usually are managed without hospitalization- remained
stable. Osteoporotic fracture has major social and health
impact. Mortality for hip fracture in hospitalized
patients is between 5 and 8%, and jumps to 20-30% dur-
ing the first year [11]; only one third of survivors
recover their pre-fracture condition.
Today, while there are effective drugs that reduce the
risk of osteoporotic fracture, yet there is no broadly
accepted criteria that can be used to estimate risks and
decide who should receive treatment. One of the actual
priorities of clinical research is to develop a set of sim-
ple and readily-available clinical data that can be used in
routine clinical practice to identify patients at high risk
of bone fracture, and to establish thresholds for thera-
peutic interventions. Such a tool would have high
impact on healthcare policies. Because hip fracture is
associated with the greatest disease burden, efforts are
being concentrated in this area.
Studies have shown that the loss of bone mineral den-
sity (BMD), as measured by dual energy x-ray absorptio-
metry (DXA) is a good predictor of fracture, particularly
in older women. The risk of osteoporotic fracture nearly
doubles for each standard deviation decrease in BMD
[12,13]. Nevertheless, there are many other factors that
contribute to osteoporotic fracture, and the loss of BMD
only identifies part of the risk. Studies have shown that
normal BMD does not mean that there is no risk of
osteoporotic fracture. Some of the Clinical Risk Factors
(CRFs) involved in osteoporotic fracture only affect
bone mass, and may be used to identify thresholds for
testing with BMD. Other CRFs are associated with
increased risk of osteoporotic fracture independently of
BMD [14,15], and looking at these will improve the pre-
diction of risk fracture [16,17]. For these reasons, differ-
ent proposals have been forwarded to estimate the risk
of osteoporotic fracture taking into account the different
CRFs (as occurs when estimating the risk of cardiovas-
cular events), with or without information on BMD.
This tools aims to predict the risk of an incident
osteoporotic fracture during a specific period of time,
usually ten years. Black et al [18], with their Fracture
Index, were among the first to propose a set of criteria
to predict vertebral, non-vertebral and hip fractures.
More recently, Robins et al. [19], and Vazquez et al., in
Spain [20], have proposed other scores although today
FRAX is the scale most widely accepted internationally
[21].
Robins et al. [19] developed a risk prediction scale for
hip fracture at five years in post-menopausal women
using data from the Women’s Health Initiative study.
The CRFs used in this scale include age, general health,
weight, height, race, physical activity, personal history of
fragility fracture after the age of 45, parental history of
hip fracture, smoking habits, current use of corticoids
and diabetes under treatment. Vazquez et al. [20] looked
at a cohort in Rotterdam to evaluate the risk of hip and
vertebral fracture at ten years in function of the subject’s
age and a risk score. The CRFs these authors examine
are BMD (<19), history of fracture before the age of 50,
parental history of hip fracture and the presence verteb-
ral deformities. The usefulness of this index in our con-
text has not yet been established, since it does not
include treatment criteria, and still needs to be validated
in the Spanish population.
The FRAX scale has been backed by the World Health
Organization and its use has been rapidly widespread. It
examines CRFs either independently or in combination
with BMD to evaluate the risk of osteoporotic fracture
at ten years, in men and women over the age of 50. The
FRAX can be used to predict the probability of hip or
other major osteoporotic fracture (clinical spine, hip,
forearm or humerus). Predictors include age, sex,
weight, height, history of prior fragility fracture, parental
hip fracture, current smoking, long-term use of oral glu-
cocorticoids, diagnosis of rheumatoid arthritis, second-
ary osteoporosis and alcohol consumption. The BMD of
the hip is included as a non-clinical factor. The original
study did not define criteria for treatment, but two later
papers have used cost-utility analysis techniques to
recommend treatment thresholds for the United King-
dom [22] and the United States [23]. These criteria, as
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the authors themselves point out, cannot be generalized
to other countries with different fracture incidence rates
and different healthcare costs.
The most recent score for estimating the individual
risk of osteoporotic fracture or hip fracture over 10
years has been developed by Hippisley-Cox et al [24] in
the UK population. These new risk prediction algo-
rithms (QFractureScores) for osteoporotic fracture and
hip fracture do not require laboratory measurement and
so can be used in primary care or for individual self
assessment. The validation statistics, especially for the
hip fracture algorithm, suggest that the QFractureScores
are likely to be useful for identifying patients at high
risk of fracture in the primary care setting in the UK
and showed improved performance compared with
FRAX.
The main implication of these results is that when
developing a scale for a specific population, or recali-
brating an international scale to the fracture incidence
of a given country, local data must be collected. Local
studies will focus on a highly heterogeneous population
that represents the real risks of a given region, and will
help to establish osteoporosis treatment thresholds.
The Valencia Health Agency, the public healthcare
network that covers close to 93% of the inhabitants of
the Region of Valencia, has implanted an electronic
medical record system called ABUCASIS. This popula-
tion-based electronic database allows carrying out longi-
tudinal studies of all the patients attending the
healthcare centers from the Region of Valencia, enabling
the monitoring of most relevant clinical data. It is now
possible to do a low-cost cohort study that will ulti-
mately lead to developing a risk scale with a 5-10 year
window for patient follow-up.
The main objective of the ESOSVAL-R is to develop a
risk prediction scale of osteoporotic fracture using data
from the Region of Valencia. This scale will allow identi-
fying intervention thresholds to support treatment deci-
sion-making in the Valencia setting, based mainly on




To develop and validate a risk prediction scale for
osteoporotic fracture in the adult population of the
Region of Valencia, Spain.
Specific objectives
1. To describe baseline characteristics of the cohort
under study and the prevalence of risk factors for osteo-
porosis. This objective will reveal the current prevalence
of risk factors for osteoporosis in men and women over
50 years in the Region of Valencia.
2. To evaluate the strength of association between risk
factors and the incidence of osteoporotic fracture at five
years for the overall population over the age of 50, and
for the five-year age-sex subgroups. This objective will
also be developed specifically for the risk of hip fracture.
3. To analyze using survival models the time relation-
ship between risk factors and the incidence of osteo-
porotic fracture and the risk of hip fracture.
4. To identify in patients with osteoporotic and hip
fracture factors of poor prognostic for survival.
5. To develop and validate a prediction scale for the
risk of osteoporotic fracture at five years, specific to the
population of the Region of Valencia, Spain.
6. To evaluate the calibration and the discrimination
capacity of the FRAX scale in the population of the
Region of Valencia and, if necessary, to recalibrate this
scale for its use in the Valencia population.
Design
This is an observational, longitudinal, prospective cohort
study with a minimum follow-up period of five years
(that can be prolonged to a maximum of ten years,
depending on the incidence of the most infrequent event,
hip fracture). The data used in the study will be obtained
primarily from the electronic clinical records (ABUCASIS
system). Complementary sources of information will also
be used to identify the follow-up outcomes.
Setting
The sample will be recruited from the Region of Valen-
cia (Spain) and, specifically, the population receiving
healthcare from the Valencia Health Agency.
Population and sample
Women and men 50 years of age and over, residing in
the Region of Valencia receiving health care in centers
where the ABUCASIS electronic clinical record system
has been implanted. Exclusion criteria included: 1) Non-
residents in the Region of Valencia, due to limitations
for long-term follow-up; 2) Individuals with cognitive
impairments that in the opinion of the collaborating
clinicians constitutes a hindrance to collecting informa-
tion about the variables used in the study; 3) People eli-
gible for public healthcare but receiving services
through private insurance companies, due to the limita-
tions for collecting data; 4) People who are physically
unable to attend their usual primary healthcare center;
institutionalization is not a criterion for exclusion as
long as the patient can go to the healthcare center; 5)
People of Asian or African decent, because of differ-
ences in prevalence of osteoporosis due to ethnic origin.
The cohort will be recruited opportunistically from
among the patients who attend the collaborating pri-
mary care centers during a 15-week period.
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The sample size has been calculated with the stpower
Cox utility of the STATA® statistics package, under the
following assumptions: Alpha error (0.05), power (0.80),
standard deviation for the densitometry T-score (0.75),
square of the multiple correlation among co-variables
(0.10), losses to follow-up of 10%, accumulated inci-
dence of hip fracture of 15‰ after five years of follow-
up and a capacity to identify as significant hazard ratios
of 33% (change in the frequency of an event associated
with a unit of change in the co-variable). These calcula-
tions results in a sample size of 14,122 individuals over
the age of 50 in whom 180 hip fractures are expected to
occur at five years of follow-up. The sample will be dis-
tributed according to the age and sex structure of the
population over the age of 50 in the Region of Valencia
and will be assigned in groups of 36 cases among the
approximately 400 participating “practices” (two colla-
borating health care professionals, typically with one
doctor and one nurse, per “practice”) in order to be able
to build a sample that is faithful to the structure of the
population of the Region.
Data sources
The main source of data will be the ABUCASIS electro-
nic clinical records. For the outcome variables, this
source will be completed with hospital morbidity
records (Discharge Data sets and other systems being
implanted), hospital accident and emergency records,
and the regional Ministry of Health’s mortality registry.
Baseline data, including the patient’s risk factors at the
time of recruitment into the cohort, will be collected
during the initial visit, using a new modified version of
the ABUCASIS specifically developed to collect informa-
tion about the variables used in the study that were not
routinely found in clinical records. The results of pre-
vious exams (x-rays or densitometry) that may have
been performed on the patients will be included in the
initial evaluation (information about previous fractures
and densitometry values). In the case of densitometry
results, the information that will be included in the
initial evaluation will be from examinations done in a
period of ± 2 years at the time of recruitment.
Main endpoint
This study’s main endpoint is a major osteoporotic frac-
ture that occurs during the follow-up period of the
study. Major osteoporotic fracture is defined as a new
fracture of the hip (not present at the time of recruit-
ment), a clinical fracture of the vertebrae or a proximal
fracture of the humerus or wrist. Fractures derived from
severe traumatism (traffic accidents, collisions, gravita-
tional trauma) will not be included, nor will pathological
fractures due to other causes (bone cancer, metastasis to
the bone, and Paget’s disease established through
diagnosis).
Secondary endpoints
The study also contemplates two secondary endpoints:
osteoporotic fracture of the hip and mortality due to
any cause.
Other variables
The independent variables used in this study were
selected after reviewing the literature and current prac-
tice guidelines, and includes the patient’s age, gender,
weight and height with a calculation of the BMI, smok-
ing habits, drinking habits, exercise habits, history of
parental hip fracture, low calcium intake, untreated
hypogonadism in men or women, rheumatoid arthritis,
other metabolic bone diseases excluding hypogonadism,
use of oral glucocorticoids, use of drugs affecting bone
metabolism other than glucocorticoids, previous osteo-
porotic fracture, high risk of fall, prolonged immobiliza-
tion, densitometric osteoporosis of the lumbar spine
established through DXA (T score for L2-L4), densito-
metric osteoporosis of the hip established through DXA
in the total hip or the femur neck (T score) and treat-
ments for osteoporosis. The participating physicians will
be trained in the management of these variables and
will be given a procedures manual containing all perti-
nent definitions. Information about antiresorptive treat-
ment will be collected from the GAIA system, the
electronic prescription system associated with the ABU-
CASIS that currently covers 95% of all prescriptions dis-
pensed in the Region. It records all the information
about the drug prescribed, along with its dosage and the
length of treatment.
Development of the study
Milestones of the study included: the selection and
training of the participating clinicians, the selection of
patients, the cohort baseline data analysis, the prelimin-
ary analysis and the analysis at the end of the follow up
period (figure 1).
Selection and training of the participating clinicians
Approximately 800 clinicians will be selected for par-
ticipation (family doctors and nurses) from the 23
Health Departments in the Region of Valencia which
have implanted the ABUCASIS system and chose to
participate voluntarily in the study. In order to sti-
mulate involvement in ESOSVAL, the Valencia
Health Agency have incorporated the participation in
the study into the governance contract with the
Health Departaments, and linked it to the existing
system of economic incentives associated to quality
indicators.
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Selection of patients
Patients will be recruited through the participating pri-
mary healthcare centers over a 18-week period. The
clinicians will select 36 patients opportunistically as they
attend the medical practices, distributing them for every
day of the week and according to the healthcare centers
different schedules. The minimum recommended
recruitment frequency is two patients per week, for the
18-week period until reaching 36 recruits with the pro-
file (age and sex) that has been assigned to each partici-
pating clinician by the research group.
Follow-up
In order to develop the scales necessary to meet our
research goals, follow-up must be long-term, between
five to ten years, so that a high enough number of hip
fractures have occurred for analysis to be significant (a
Figure 1 Flow diagram of the study.
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fracture in any other location is much more frequent
and does not require as long a follow-up period as con-
templated in this study). During the initial medical visit,
information will be collected and/or completed concern-
ing all of the variables that will be used in the calcula-
tion of the risk of osteoporotic fracture. During the
follow-up period, the research group will keep an
exhaustive record of all new fractures, consulting all of
the Valencia Health Agency’s available information sys-
tems to do so. At five years (and if the researchers
decide to extend the study, at ten years) the variables
explored during the initial visit with the clinician will be
reviewed. The fieldwork will begin in 2010, and be com-
pleted in 2015; it will be extended to 2019 if necessary.
Ethical aspects
The study will be conducted according to the interna-
tional standards of the International Guidelines for Ethi-
cal Review of Epidemiological Studies (Council for
International Organizations of Medical Sciences-
CIOMS-Geneva, 1991) and the recommendations of the
Spanish Society of Epidemiology about the review of
ethical aspects of epidemiological research.
The ESOSVAL-R study has been reviewed and
approved by the Committee for Ethics and Clinical
Trials of the Center for Public Health Research. The
ESOSVAL-R is a naturalistic, observational study under-
taken as part of routine clinical practice, with no inter-
vention (apart from training of participating clinicians)
with the patients included in the study. No additional
risks associated with participation are anticipated, as no
additional diagnosis, evaluation or treatment will be pro-
vided, apart from what the attending physician deems
appropriate.
Confidentiality of the data
All information relative to the patients’ identity will be
considered confidential to all effects. Data concerning
patients that is collected from the ABUCASIS system
during the study will be documented anonymously,
making impossible to use this information to identify
the patients. The only connection between these data
and the patient will be a simple code used exclusively
for this study, in such a way that only the ABUCASIS
system will be able to associate the data to an identified
or identifiable individual. The data generated during the
study will be handled as stipulated in the Law 5/1999
and corresponding norms. All of the researchers with
access to the data used in the study will be required to
sign a document guaranteeing confidentiality.
Informed consent
Although the study does not involve the randomization
of the sample or the application of further interventions,
prior to inclusion, all patients must read the “Patient
Information Form” and sign a document giving consent,
and granting the researchers access to information con-
tained, in an anonymous way and only for the purposes
of this study, in their clinical records.
Statistical analysis
Once the recruiting process has been completed, the
cohort baseline data will be analyzed. A description will
be made of the patients’ characteristics along with their
current risk factors. The analysis will be stratified by
five-year age-sex subgroups. The appropriate parameters
(means, proportions) will be used with each variable
with their corresponding 95% confidence intervals
(CI95%). A bi-variable analysis will also be made to eval-
uate the relationships between risk factors that are of
most interest. Simple Odds Ratios (OR) will be applied
to estimate the strength of association and, when neces-
sary, multiple logistic regression models will be used.
At two and five years of follow-up, an analysis will be
made of the strength of association between the risk fac-
tors and the incidence of osteoporotic fracture in all
locations and in the hip. For this, bi-variable analysis
and Cox’ proportional hazards models will be used.
Additionally, a specific model will be developed to ana-
lyze the probability of death once a fracture has
occurred (controlling for the effect of the different types
of fractures).
Next, the most parsimonious of Cox’ proportional
hazards models will be applied to two-thirds of the sam-
ple (approximately 10,000 subjects randomly selected) to
develop a scale to predict the risk of osteoporotic frac-
ture. The scale’s prediction capacity will be evaluated
with the C statistic, and its calibration will be evaluated
with the Hosmer-Lemeshow test, or a similar test. The
predictive weights of the risk factors obtained in this
model will be applied to the remaining third of the data-
base (approximately 5,000 subjects) to evaluate whether
prediction capacity (C statistic > 0.75) and calibration
(non-significant Hosmer-Lemeshow test) are maintained.
Scaling techniques will then be applied to construct a
simplified scale on the basis of the validated model.
Finally, the calibration and the capacity for discrimina-
tion of the FRAX scale will be evaluated in the popula-
tion of the Region of Valencia, Spain. If necessary, the
FRAX will be recalibrated to make it more appropriate
for the population in question. This time, the weights of
the original scale will be used in conjunction with the
incidence of osteoporotic fracture derived from our
study. If the scale shows poor prediction capacity (statis-
tics < 0,75), or if it is not correctly calibrated, it will be
recalibrated with the weights derived from our own scale.
Discussion
Observational studies have various inherent limitations.
It is important to appraise these in an effort to minimize
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their effects or, at least to account for them when inter-
preting results. The most important limitations asso-
ciated with the ESOSVAL-R study include the following:
1. Selection biases: It is virtually impossible to elimi-
nate all biases from the selection process. First, the peo-
ple most likely to visit the doctor with the greatest
frequency are those who are very old or very sick and
there is, thus, a greater possibility that these people will
be selected for participation. Clinicians may also tend to
select patients who are easier to interview (people with
higher educational level), to the detriment of other can-
didates. In order to reduce the possibility of either of
these situations’ occurring, this point is specifically
stressed to the clinicians during their training sessions.
A selection outline, based on the healthcare centers’
schedules and patient turns, has also been developed to
ensure equitable selection.
2. Information biases when data is missing from the
electronic clinical record: Although this problem is ever-
present when a study is based on data from real clinical
practices, various strategies will be applied to minimize
its effect: a) It will be necessary to guarantee that all the
participating clinicians are up to date on the topic of
osteoporosis, that during medical visits they all respond
in a similar fashion and that the quality of the electronic
clinical records is as high as possible. To this end a
training course will be given to all the clinicians selected
for participation. These participants will be required to
attend class and to complete further on-line training in
the skills and knowledge necessary to manage osteo-
porosis. b) The electronic clinical records system has
been modified to ensure that data is recorded correctly
and that the registers are maintained uniformly after the
recruits’ initial medical visits, and during the follow-up
period. These improvements in the electronic medical
records system applies to all healthcare centers of the
Valencia Health Agency, and not only those participat-
ing in this study.
3. Biases due to interventions and maturation: Here
the risks are twofold. On the one hand, all the partici-
pating clinicians will be receiving specific training to
prepare them for the study. On the other, since this is
an open study, it may be affected by the doctors’ learn-
ing curves throughout the process. Because of these two
factors, follow-up may be more thorough in the partici-
pating patients, and they may receive better care than
the population at large. This may translate into differ-
ences in the incidence of fractures in the sample cohort
and in the general population which, in turn, may lead
to underestimating the impact of the risk factors for
fracture. Any open study is susceptible to this limitation
and it’s difficult to handle. However, in the case of the
ESOSVAL, the training for healthcare professionals is
programmed for the beginning of the study, and we
hope that this will minimize the impact of this bias.
Furthermore, another study will be designed in conjunc-
tion with this one to look at the patients of doctors not
participating in the ESOSVAL initiative in an effort to
identify possible differences in patient management.
4. Biases associated with misclassification: This bias
will occur in either of two cases: when fractures of inter-
est are not identified during the follow-up phase or,
alternatively, when fractures that have not occurred dur-
ing the follow-up period are improperly identified as
new ones (identifying as fractures occurring during the
follow-up period injuries already existing at the time of
recruitment, which should have been classified as pre-
vious fractures). To limit this problem, different data
sources will be used to properly identify all fractures
(ABUCASIS, hospital discharge data, A&E records).
Doctors will also be trained to distinguish between
already existing and new fractures.
In spite of these limitations, ESOSVAL have several
strengths. The study will usher in improvements in the
electronic clinical records used throughout the Region
and provide training to 800 healthcare professionals and
this alone can have a direct impact on the quality of the
clinical information registered, and on the attention
given to one of today’s most prevalent diseases. How-
ever, the most innovative fact of ESOSVAL is that it will
use routine electronic medical records to follow-up a
cohort of 14,500 subjects. Although the potential of
these databases for research is obvious, no project like
ESOSVAL has been conducted in Spain to date with a
design like ours, or a similar number of patients and
participating healthcare professionals or length of fol-
low-up. This study will provide insight into the possibili-
ties and limits of the use of these systems for research
purposes. Finally, the ESOSVAL study will provide
information about the real incidence of osteoporotic
fracture in the population of the Region of Valencia
(which can be useful for the rest of Spain, where there
are no studies of incidence) and about the risk factors
for fracture in this context. Ultimately, it will help estab-
lish a prediction scale for osteoporotic fracture. Not only
will this scale constitute a useful prognostic tool, when
further developed with research on cost-utility, it will
help establish efficient criteria to identify the level of
risk at which treatment should be initiated.
Abbreviations
BMD: bone mineral density; DXA: dual energy x-ray absorptiometry; CRF:
clinical risk factors; OR: odds ratio.
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